2. Academic Validation
  3. The topoisomerase inhibitor CPT-11 prevents the growth and metastasis of lung cancer cells in nude mice by inhibiting EGFR/MAPK signaling pathway

The topoisomerase inhibitor CPT-11 prevents the growth and metastasis of lung cancer cells in nude mice by inhibiting EGFR/MAPK signaling pathway

  • Heliyon. 2023 Apr 27;9(5):e15805. doi: 10.1016/j.heliyon.2023.e15805.
Yingqiu Yin 1,  Junling Xie 1,  Feng Peng 1,  Liming Tan 2,  Yun Xiao 1,  Huiying Zheng 1,  Lingzhi Yin 1,  Huijing Situ 3,  Shanqiang Zhang 4 5
Affiliations

Affiliations

  • 1 Respiratory Medical Department, Yue Bei People's Hospital, Shantou University Medical College, Shaoguan City, Guangdong Province, China.
  • 2 Science and Education Department, Yue Bei People's Hospital, Shantou University Medical College, Shaoguan City, Guangdong Province, China.
  • 3 Department of Radiotherapy, Yue Bei People's Hospital, Shantou University Medical College, Shaoguan City, Guangdong Province, China.
  • 4 Department of Anatomy, Shantou University Medical College, Shantou City, Guangdong Province, China.
  • 5 Medical Research Center, Yue Bei People's Hospital, Shantou University Medical College, Shaoguan City, Guangdong Province, China.
PMID: 37251857 DOI: 10.1016/j.heliyon.2023.e15805
Abstract

Objective: The Topoisomerase Inhibitor CPT-11 has been applied in treatment of multiple Cancer types. Here, we probed into the possible mechanism of CPT-11 in affecting growth and metastasis of lung Cancer (LC) cells, with involvement of the EGFR/MAPK pathway.

Methods: The target protein of CPT-11 was screened through bioinformatics analysis, and the LC-related microarray datasets GSE29249, GSE32863 and GSE44077 were obtained for differential analysis for identifying the target protein. A subcutaneous xenograft tumor model and a metastatic tumor model were constructed in nude mice for in vivo mechanism verification of the regulatory role of CPT-11 in LC through modulation of EGRF/MAPK pathway.

Results: Bioinformatics analysis showed that EGFR was the target protein of CPT-11. In vivo animal experiments confirmed that CPT-11 enhanced LC cell growth and metastasis in nude mice. CPT-11 could inhibit activation of EGFR/MAPK pathway. EGFR promoted LC cell growth and metastasis in nude mice through activation of the MAPK pathway.

Conclusion: The Topoisomerase Inhibitor CPT-11 may prevent LC growth and metastasis by inhibiting activation of EGFR/MAPK pathway.

Keywords

CPT-11; EGFR; Lung cancer; MAPK pathway; Metastatic tumor model; Subcutaneous xenograft tumor model; Topoisomerase inhibitor.

Figures
Products